H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Announces Acquisition of Kineta, Inc.
- TuHURA Biosciences Expands Board with New Appointment
- TuHURA Biosciences appoints Craig Tendler to board of directors
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- TuHURA Biosciences initiated with a Buy at H.C. Wainwright